Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone

Kasper, Siegfrieda; Montagnani, Ginob; Trespi, Graziellac; Di Fiorino, Mariod

International Clinical Psychopharmacology: January 2015 - Volume 30 - Issue 1 - p 14–22
doi: 10.1097/YIC.0000000000000053
ORIGINAL ARTICLES
Buy

The present analysis assessed the efficacy of extended-release quetiapine fumarate (quetiapine XR) versus risperidone in patients with schizophrenia and depressive symptoms [Hamilton Depression Rating Scale (HAM-D) score≥20 and a HAM-D item 1 score≥2]. This was a subanalysis of patients with schizophrenia from a randomized, open-label, parallel-group, flexible-dose study (NCT00640562) that also enrolled patients with schizoaffective disorder. The primary endpoint of this noninferiority study was change from baseline to week 12 in Calgary Depression Scale for Schizophrenia score (per protocol population). Overall, 114 patients received quetiapine XR (n=60; 400–800 mg/day) or risperidone (n=54; 4–6 mg/day). Change in Calgary Depression Scale for Schizophrenia score was greater for quetiapine XR than for risperidone [least squares means: −7.2 vs. −4.8; treatment difference 2.4 (95% confidence interval 0.3–4.6; P<0.05)]. Adverse events (≥3%) among patients receiving quetiapine XR were sedation, somnolence, and dry mouth, and among those receiving risperidone were anxiety, insomnia, asthenia, hyperprolactinemia, and somnolence. Abnormally high prolactin levels were reported for 57.6 and 8.1% of patients receiving risperidone and quetiapine XR, respectively. Quetiapine XR was superior to risperidone at reducing depressive symptoms in patients with schizophrenia.

aDepartment of Psychiatry and Psychotherapy, Medical University, Vienna, Austria

bFormer AstraZeneca, Research & Development, Milan

cAstraZeneca, Research & Development, Milan

dVersilia Hospital, Camaiore, Italy

Kasper S, Di Fiorino M, Montagnani G, Trespi G. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizophrenia. Poster presented at the 2nd International Congress on Neurobiology, Psychopharmacology, and Treatment Guidance, Thessaloniki, Greece, 24–27 November 2011.

Correspondence to Siegfried Kasper, MD, PhD, Department of Psychiatry and Psychotherapy, Medical University of Vienna, AKH, Währinger Gürtel 18-20, A-1090 Vienna, Austria Tel: +43 1 40400 3568; fax: +43 1 40400 3099; e-mail: biol-psychiatry@meduniwien.ac.at

Received April 29, 2014

Accepted September 23, 2014

© 2015 Wolters Kluwer Health | Lippincott Williams & Wilkins